Clene Inc. (CLNN)
Oxford Ledge is still expanding full research coverage of CLNN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A clinical-stage biotech company develops catalytic gold nanocrystals to treat neurodegenerative diseases by restoring cellular energy production.
SEC filings
- 8-K Entry into material agreement; Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-05-22
- 8-K Entry into material agreement; Results of operations / financial condition; Financial statements and exhibits 2026-05-14
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-05-05
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-05-04
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for CLNN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CLNN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.